The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | POCHI: pembrolizumab, CAPOX and bevacizumab in pMMR/MSS CRC at ESMO 2024
David Tougeron, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the preliminary results of the Phase II POCHI trial (NCT04262687), which evaluated pembrolizumab with CAPOX and bevacizumab in pMMR/MSS metastatic colorectal cancer (mCRC) with high immune infiltrate. The study aimed to assess progression-free survival (PFS) at 10 months and secondary outcomes like overall survival and response rates; preliminary results showed a high disease control rate (DCR). This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
